Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nomogram Validation in Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
jRCT1050250233Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Single-arm trial of nivolumab and ipilimumab in renal cell carcinoma (RCC), sponsored by Ono Pharmaceutical. Primary endpoint: AUC values of ROC curves. Started Feb 2026; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT1050250233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050250233.